Results 31 to 40 of about 7,376 (199)
Automated Metadata Review to Support Result Release in Quantitative Liquid Chromatography Coupled With Tandem Mass Spectrometry Applications. [PDF]
Anal Sci AdvQuantitative isotope‐dilution liquid chromatography coupled with tandem mass spectrometry analyses generate extensive metadata that require time‐consuming manual validation in laboratory workflows. We developed MSVal, an Excel‐based tool that applies predefined quality criteria to automatically evaluate results and highlight deviations.
Endt V, Habler K, Vogeser M.
europepmc +2 more sources
Reproductive Futures in Focus: Contraceptive Choices Among Individuals With Cystic Fibrosis-Patterns, Preferences, and Influencing Factors. [PDF]
Pediatr PulmonolABSTRACT Introduction Advancements in the care of people with cystic fibrosis (PwCF) have made discussions about reproductive health increasingly important. Rising rates of both intended and unintended pregnancies highlight the need for effective contraception counseling.
Lonabaugh KP +4 more
europepmc +2 more sources
, 2018 BACKGROUND & OBJECTIVE: Since the release of ivacaftor-lumacaftor, several red-flags have been raised that highlight the clinical efficacy of this combination strategy that may be limited due to antagonistic drug-drug interactions.
Schneider, EK
core +1 more source
The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.
PLoS ONE, 2020 ImportanceSinonasal symptoms in patients suffering from cystic fibrosis can negatively influence the quality of life and sinuses can be a niche for pathogens causing infection and inflammation leading to a decrease of lung function.
Romee Gostelie +7 more
doaj +1 more source
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
European Respiratory Review, 2020 Drug compounds that augment the production and activity of the cystic fibrosis (CF) transmembrane regulator (CFTR) have revolutionised CF care. Many adults and some children with CF suffer advanced and severe lung disease or await lung transplantation ...
Michal Shteinberg +1 more
doaj +1 more source
Elexacaftor/Ivacaftor/Tezacaftor: First Approval
, 2019 Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding. Conflict of interest: Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article ...
Sheridan M. Hoy (4897468)
core +1 more source
Advanced Science, EarlyView.High‐throughput Differential Dynamic Microscopy measures frequency‐resolved mechanical fingerprints from 3 to 10 μL$\umu{\rm L}$ mucus samples using only a few minutes of operator attention per sample. This automated analysis enables scalable mucus phenotyping for translational research by distinguishing mechanical heterogeneity among donors, disease ...
Feng Ling +18 more
wiley +1 more source
Children, 2023 Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) is a new CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator treatment, used over the last few years, which has shown an improvement in different clinical outcomes in patients with cystic ...
Nikoletta Kapouni +3 more
doaj +1 more source
Summary data for S8, R117H-5T, (±) ivacaftor.
, 2014 (A) Mean ± SEM for the final (30 min) volume of C-sweat secretion per gland (50–53 glands measured for each test) (±) ivacaftor. (B) C-sweat/M-sweat ratios expressed as percent of the WT mean. Results are means ± SEM for 49–53 glands per test.
Jessica E. Char (476386) +11 more
core +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Olfactory dysfunction (OD) is an increasingly recognized but under‐investigated comorbidity of cystic fibrosis (CF). Its prevalence, assessment methods, and response to CF‐directed treatment, including highly effective modulator therapy (HEMT) remains incompletely characterized.
Luca Cox +5 more
wiley +1 more source